GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and Relation Therapeutics, using their Lab in the Loop platform to discover novel targets for osteoarthritis, systemic sclerosis and other fibrotic mechanisms, supporting data-tech driven approach in respiratory, immunology and inflammation; and multi-target strategic alliance with GSK to develop breakthrough treatments for people afflicted with Parkinson's disease; as well as collaboration with Flagship Pioneering to discover novel medicines and vaccines. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in London, the United Kingdom.

GSK plc American Depositary Shares (Each representing two)

An announcement from GlaxoSmithKline ( ($GB:GSK) ) is now available. GSK plc has continued its share buyback programme, repurchasing 345,000 ordina...

GSK Expands Treasury Stock with Latest Tranche of Share Buybacks

An update from GlaxoSmithKline ( ($GB:GSK) ) is now available. GSK has reported that as of 31 March 2026 its issued share capital comprised 4,316,1...

GSK Updates Market on Total Voting Rights and Share Capital

GlaxoSmithKline ( ($GB:GSK) ) just unveiled an announcement. GSK plc has repurchased 340,000 of its ordinary shares on 31 March 2026 through BNP Pa...

GSK Expands Share Buyback, Lifts Treasury Holdings to 6.31% of Voting Rights

Goldsky Resources ( ($TSE:GSKR) ) just unveiled an update. Goldsky Resources reported unaudited fourth-quarter and full-year 2025 results that high...

Goldsky Resources Posts Transformed 2025 Balance Sheet as Nordic Gold Portfolio Expands

GlaxoSmithKline ( ($GB:GSK) ) just unveiled an update. GSK has continued its share buyback programme, repurchasing 340,000 ordinary shares on 30 Ma...

GSK Buys Back 340,000 Shares Under Ongoing Repurchase Programme

GlaxoSmithKline ( ($GB:GSK) ) has provided an announcement. GSK has announced that China’s National Medical Products Administration has accepted fo...

GSK’s Hepatitis B Drug Bepirovirsen Enters China Regulatory Review as Potential First-in-Class Cure

J.P. Morgan analyst Zain Ebrahim maintained a Sell rating on GlaxoSmithKline today and set a price target of £17.00. According to TipRanks, Ebrahim...

J.P. Morgan Sticks to Its Sell Rating for GlaxoSmithKline (GSK)

An update from GlaxoSmithKline ( ($GB:GSK) ) is now available. GSK plc has continued its share buyback programme, repurchasing 345,000 ordinary sha...

GSK expands share buyback, lifts treasury stake to 6.28%

GlaxoSmithKline ( ($GB:GSK) ) just unveiled an update. GSK has had its marketing authorisation application for bepirovirsen accepted for review by ...

GSK’s Hepatitis B Drug Bepirovirsen Accepted for EMA Review After Positive Phase III Data

In a report released yesterday, from Shore Capital reiterated a Buy rating on GlaxoSmithKline. The company’s shares closed yesterday at p2,054.00. ...

GlaxoSmithKline (GSK) Gets a Buy from Shore Capital

GlaxoSmithKline ( ($GB:GSK) ) just unveiled an update. GSK disclosed that Maya Martinez-Davis, its President for the U.S. market, acquired a small ...

GSK Reports Routine ADS Acquisition by U.S. President Martinez-Davis

GlaxoSmithKline ( ($GB:GSK) ) just unveiled an update. GSK has disclosed a series of share purchases by its chair and several independent non‑execu...

GSK directors boost holdings with coordinated share purchases

In a report released yesterday, Justin Smith from Bernstein maintained a Buy rating on GlaxoSmithKline, with a price target of £27.50. The company’...

GlaxoSmithKline (GSK) Receives a Buy from Bernstein

GlaxoSmithKline ($GSK) announced an update on their ongoing clinical study. GSK Targets Tough Ovarian Cancer With New Phase 3 Drug Study The phase ...

GSK Advances New Phase 3 Trial in Hard-to-Treat Ovarian Cancer: What Investors Should Watch

The latest announcement is out from GlaxoSmithKline ( ($GSK) ). On 19 March 2026, GSK announced that the U.S. Food and Drug Administration approved...

GSK Wins First U.S. Approval for Lynavoy in PBC-Related Itch, Advancing Hepatology Push

GlaxoSmithKline ( ($GSK) ) has provided an update. On March 16, 2026, GSK plc reported that its Chief People Officer, Diana Conrad, acquired 12.430...

GSK Discloses Chief People Officer’s March 16 ADS Purchase Under Pension Plan

The latest announcement is out from GlaxoSmithKline ( ($GSK) ). On 17 March 2026, GSK plc repurchased 732,112 of its ordinary shares, with prices r...

GSK Expands March Buyback With 732,112-Share Repurchase

Goldsky Resources ( ($TSE:GSKR) ) just unveiled an update. Goldsky Resources has mailed and filed meeting materials for an April 9 special sharehol...

Goldsky Seeks Shareholder Approval to Gain Full Control of Barsele Gold Project

The latest update is out from GlaxoSmithKline ( ($GSK) ). On 13 March 2026, GSK reported that its US president, Maya Martinez-Davis, acquired a sma...

GSK Discloses Notional ADS Acquisition by US President Under Executive Savings Plan

GlaxoSmithKline ( ($GSK) ) has provided an announcement. On 16 March 2026, GSK repurchased 628,000 ordinary shares of 31.25 pence each through BNP ...

GSK Boosts Treasury Stock With Latest Share Buyback on 16 March 2026

An update from GlaxoSmithKline ( ($GB:GSK) ) is now available. GSK has disclosed a series of routine share transactions by senior executives under ...

Current Quarter	$1.18	Next Quarter	$1.25
Current Year	$4.84	Next Year	$5.09
QoQ Growth	+5.9%	YoY Growth	+5.2%
3Y EPS CAGR	-23.0%	Target Price	$54.63
Consensus	Buy	Upside	-3.6%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	GSK	$56.69	0.00%	3.88M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	GSK	$56.69	0%	3.88M
3
4
5
6

GSK

GSK

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get GSK plc American Depositary Shares (Each representing two) Data in Excel

Get GSK plc American Depositary Shares (Each representing two) Data in Excel